CAM
RVMD icon

Cormorant Asset Management’s Revolution Medicines RVMD Stock Holding History

Cormorant Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,895,066
Closed -$45.1M – 81
2022
Q4 		$45.1M Sell
1,895,066
-100,000
-5% -$2.13M 3.02% 9
2022
Q3 		$39.3M Hold
1,995,066
– – 2.75% 9
2022
Q2 		$38.9M Hold
1,995,066
– – 2.94% 6
2022
Q1 		$50.9M Sell
1,995,066
-436,786
-18% -$9.51M 3.91% 7
2021
Q4 		$61.2M Sell
2,431,852
-712,848
-23% -$20.1M 3.64% 7
2021
Q3 		$86.5M Sell
3,144,700
-193,466
-6% -$5.63M 3.52% 5
2021
Q2 		$106M Buy
3,338,166
+813,166
+32% +$28.4M 3.6% 7
2021
Q1 		$116M Buy
2,525,000
+29,934
+1% +$1.34M 2.58% 9
2020
Q4 		$98.8M Sell
2,495,066
-145,111
-5% -$5.74M 2.35% 10
2020
Q3 		$91.9M Buy
2,640,177
+3,516
+0.1% +$97.4K 3.53% 4
2020
Q2 		$82.7M Sell
2,636,661
-130,417
-5% -$4.1M 3.16% 7
2020
Q1 		$60.6M Buy
+2,767,078
New +$76.6M 2.82% 12

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cormorant Asset Management's RVMD Position: Q1 2023 in Review

Cormorant Asset Management sold out of Revolution Medicines (RVMD) in Q1 2023, closing a stake of 1,895,066 shares — an estimated $45.1M sold.

Cormorant Asset Management first reported a position in RVMD in Q1 2020 and held it in 12 quarters. The position peaked at $116M in Q1 2021. 152 funds tracked by Wall St. Rank hold RVMD as of Q1 2023.

  • Cormorant Asset Management reported no remaining Revolution Medicines position as of Q1 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 1,895,066 Revolution Medicines shares in Q1 2023, an estimated $45.1M.
  • Cormorant Asset Management first reported a position in Revolution Medicines in Q1 2020 and held it in 12 quarters.
  • Cormorant Asset Management's Revolution Medicines position peaked at $116M in Q1 2021.
  • 152 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2023.

Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.